Hualan Biological Engineering (002007.SZ) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

002007.SZ · Stock Price

CNY 14.42-1.98 (-12.07%)

Market Cap: $3.9B

Historical price data

Overview

Hualan Biological Engineering's mission is to safeguard public health through the research, development, and large-scale manufacturing of high-quality vaccines and plasma-based therapeutics. The company has achieved a leading market share in China's influenza vaccine segment and built a formidable, asset-heavy business model anchored by its extensive plasma station network and established manufacturing platforms. Its strategy focuses on defending its core franchises while strategically investing in next-generation vaccine technologies, including cell culture-based production and conjugate vaccines, to drive future growth and enhance pandemic preparedness.

Infectious DiseasesHematologyImmunology

Technology Platform

Hualan Bio leverages a multi-platform manufacturing strategy encompassing traditional egg-based and plasma fractionation processes, complemented by strategic investments in next-generation cell culture, conjugate, and recombinant vaccine technologies.

Pipeline

7

7 drugs in pipeline3 in Phase 3

Drug	Indication	Stage
Inactivated influenza split vaccine	Human Influenza	Approved
Influenza split vaccine of 15 μg HA + Influenza split vaccin...	Influenza	Phase 3
Influenza Split Vaccine + Inactivated Influenza Vaccine	Influenza	Phase 3
ACYW135 Meningococcal Polysaccharide Vaccine + A+C Meningoco...	Meningitis	Phase 3
Group ACYW135 Meningococcal Polysaccharide Vaccine	Meningitis	Phase 2

Funding History

1

IPOUndisclosedUndisclosedJun 15, 2004

Opportunities

Significant growth lies in increasing influenza vaccination rates in China, launching high-value conjugate vaccines like PCV13, and expanding the portfolio of specialized plasma-derived therapeutics.

The company's vertical integration and strong balance sheet position it to capitalize on market consolidation and public health infrastructure investments.

Risk Factors

Key risks include dependency on government vaccine procurement policies, execution challenges in transitioning to next-generation manufacturing platforms, potential supply constraints or safety issues in the plasma collection business, and intensifying competition from both domestic innovators and multinational corporations.

Competitive Landscape

Hualan Bio holds a dominant position in China's influenza vaccine market and is a top-three player in plasma therapeutics, competing primarily with large domestic firms like Tiantan Biological and Shanghai RAAS. Its main competitive threats stem from multinationals with advanced vaccine platforms and emerging domestic biotechs pursuing novel modalities like mRNA.

More companies in China →